Search

TGAAC94

It was under investigation in clinical trials to treat Inflammatory Arthritis. In 2007, one patient participating in the clinical trial died and the trial was placed on clinical hold by the FDA. … tgAAC94 is a recombinant adeno-associated virus serotype 2 (AAV2) vector containing the cDNA for a human tumor necrosis factor receptor (TNFR)-immunoglobulin (IgG1) Fc fusion (TNFR:Fc) gene.

Mequitazine

It competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. … It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.

AEOL-10150

AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.

Mebanazine

It was used in the past as an antidepressant in the 1960s, but has since been discontinued because of its hepatotoxic potential. … Mebanazine, also known as _Actomol_, is a monoamine oxidase inhibitor (MAOI) belonging to the _hydrazine_ class of chemicals.

Drotrecogin alfa

Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis. … Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology.

Propantheline

A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.

NM-702

Nissan Chemical and Taisho have been jointly developing NM-702, a drug for the treatment of arteriosclerosis obliterans. … In the USA, a Phase 2 study for intermittent claudication caused by arteriosclerosis obliterans has been successfully completed.

Selisistat

Enhances p53 acetylation in response to DNA damaging agents. … Selective inhibitor of SIRT1 that does not inhibit histone deacetylase (HDAC) or other sirtuin deacetylase family members (IC50 values are 98, 19600, 48700, > 100000 and > 100000 nM for SIRT1, SIRT2, SIRT3

Dihydroquinidine barbiturate

LY2275796

LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development. … LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases.